Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection.
about
Management of HBV and HBV/HDV-Associated Liver CirrhosisAdvances and Challenges in Studying Hepatitis B Virus In VitroChange of strategies and future perspectives against hepatitis B virus recurrence after liver transplantationHepatitis B: future curative strategiesCurrent progress in the development of therapeutic vaccines for chronic hepatitis B virus infectionImmune therapy for hepatitis BCurrent and future antiviral drug therapies of hepatitis B chronic infectionThe role of the hepatitis viruses in cholangiocarcinomaNew loci associated with chronic hepatitis B virus infection in Han ChineseInterplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts.The Role of cccDNA in HBV Maintenance.Proteomic profiling of HBV infected liver biopsies with different fibrotic stages.Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice modelA whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems.Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patientsIncreased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients.Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island.HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patientsActivation mechanisms of natural killer cells during influenza virus infectionVirus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels.Designing immune therapy for chronic hepatitis B.Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomesCXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot studyViral hepatitis: past and future of HBV and HDV.Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections.Antiviral therapies and prospects for a cure of chronic hepatitis B.Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B.Gut microbiota modulate the immune effect against hepatitis B virus infection.Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Sera of Patients at Different Phases of InfectionEmerging Role of Interleukin 22 in Hepatitis B Virus Infection: a Double-edged Sword.Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infectionImmunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after InfectionHBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse modelReversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patientsPresent and future therapies of hepatitis B: From discovery to cureElevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B.
P2860
Q26740323-ACE94F56-4AF3-4848-8470-E3688B816ABCQ26771134-0689D30A-C36E-4765-A502-431E7071588EQ26784241-7E13A85B-B6E2-4AC5-B4BA-67A6D43C7A6EQ27011623-5BA6E0EE-37D6-4321-A8C2-EF66BA614D4AQ28076279-792A920A-61B0-418C-9857-53AC80FA7480Q28078856-288287D9-6705-4AC9-B19E-48EF2FE9AEE6Q28084820-8A3A2329-610C-45C7-A394-A283259F11D0Q28288613-8C495B08-07D7-41F2-A43C-1810299DD89CQ28300932-D4E8FF1C-FDF5-4217-9ACE-7EFAA5964C91Q30854409-31A74948-45D5-4D84-8F6A-C28E56CFD78AQ32182914-D17EB04E-0B38-407F-AAF5-123B2F7558D1Q33587550-2ADA9A1F-F63B-428E-BCEF-94A642EFD874Q33927761-DBA30449-0E87-4B1B-B9C9-CAD50132B902Q33933196-2BBFE813-6036-46B1-B688-5C0A892678AFQ34082747-A303A471-331B-4E8F-9CA6-34FCACC96426Q34168451-2ED2DE7A-0D13-4D6F-8109-C2A6F1E21AB3Q34235321-C5858894-6630-47C1-83BB-C88C9BE00C81Q34335676-87C0345B-C029-4026-9991-057C0FEA2767Q34505113-84AF879D-9C09-4EE8-AC49-51AF9AA217DFQ34540276-FCF7DC62-826C-46C7-B9A9-B1CEB1FF0315Q34764269-01ABFE6F-8E94-4BC2-AA3D-F72CFCA606B8Q34825732-CD69EDB5-B1FF-48C9-B09B-0C565E47D22CQ34998226-2613DA95-B836-471C-9FC9-463DE036942EQ35017075-4530D818-4440-458E-B7C9-7CBA06506D68Q35045045-3E36CFEA-E09C-4D06-A5E8-A98CF0F7A164Q35075107-4848EE71-B8C9-4F6B-A9E5-0A7A243F06CAQ35102451-8685A029-788F-4F0F-93DA-95CDE6662477Q35245231-937B269D-AB72-4603-BEF5-93DC97B3F02AQ35616664-0D6600DC-B76F-4F6F-B6A4-76462B675F69Q35745517-53F9B452-8BA6-435F-85C2-CD3A324F3027Q35757727-BE458ED3-719A-4A5A-9F33-725B88740A6DQ35906051-DC04C330-873A-4C1F-B8ED-57B9E2BE2E97Q36018196-EC240BC1-3F9F-41C0-94AA-6568F5FEDFE5Q36073739-831EB9D2-507E-4DD4-9AF6-E17E497A6B2BQ36251481-8C21AA40-3481-433E-AABC-CE18F5946895Q36255419-F9E0B903-0DC9-4584-91EC-BDAAEB707BDBQ36302689-BDB8ECC7-5B24-4B69-95D8-9D5AB89D2661Q36302694-20F9CD18-BEE0-4588-BEC4-B3FFC2C42280Q36378278-705EBA51-DC0A-4DDE-A6F4-BC56332FE9DEQ36875021-36A5D0AB-8C64-457D-9F73-19A29A58FAAA
P2860
Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Innate and adaptive immune res ...... ne control of viral infection.
@en
Innate and adaptive immune res ...... ne control of viral infection.
@nl
type
label
Innate and adaptive immune res ...... ne control of viral infection.
@en
Innate and adaptive immune res ...... ne control of viral infection.
@nl
prefLabel
Innate and adaptive immune res ...... ne control of viral infection.
@en
Innate and adaptive immune res ...... ne control of viral infection.
@nl
P1433
P1476
Innate and adaptive immune res ...... ne control of viral infection.
@en
P304
P356
10.1136/GUTJNL-2011-301073
P407
P577
2011-12-09T00:00:00Z